Edition:
United States

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

13.18USD
4:00pm EDT
Change (% chg)

$0.05 (+0.38%)
Prev Close
$13.13
Open
$13.20
Day's High
$13.46
Day's Low
$12.99
Volume
392,800
Avg. Vol
422,673
52-wk High
$14.22
52-wk Low
$1.48

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 2.55
Market Cap(Mil.): $1,227.83
Shares Outstanding(Mil.): 87.58
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -0.57 -- --
ROI: -40.62 -5.30 13.11
ROE: -42.60 -6.83 15.11

BRIEF-Arrowhead Pharmaceuticals Presents Preclinical Data On Expanding Cardiometabolic Pipeline

* ARROWHEAD PHARMACEUTICALS PRESENTS PRECLINICAL DATA ON EXPANDING CARDIOMETABOLIC PIPELINE

May 11 2018

BRIEF-Arrowhead Pharmaceuticals Reports Qtrly Loss Per Share $0.18

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 SECOND QUARTER RESULTS

May 08 2018

BRIEF-Arrowhead Pharmaceuticals Arrowhead Begins Dosing In Phase 1/2 Study Of ARO-HBV

* ARROWHEAD BEGINS DOSING IN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF CHRONIC HEPATITIS B Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 27 2018

BRIEF-Arrowhead Begins Dosing In Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD BEGINS DOSING IN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE Source text for Eikon: Further company coverage:

Mar 12 2018

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1 Study Of ARO-AAT For Treatment Of Alpha-1 Liver Disease

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1 STUDY OF ARO-AAT FOR TREATMENT OF ALPHA-1 LIVER DISEASE

Feb 22 2018

BRIEF-Arrowhead Pharmaceuticals Receives Orphan Drug Designation For ARO-AAT

* ARROWHEAD PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FOR ARO-AAT

Feb 15 2018

BRIEF-Arrowhead Receives Regulatory Clearance To Begin Phase 1/2 Study Of Aro-Hbv For Treatment Of Hepatitis B

* ARROWHEAD RECEIVES REGULATORY CLEARANCE TO BEGIN PHASE 1/2 STUDY OF ARO-HBV FOR TREATMENT OF HEPATITIS B Source text for Eikon: Further company coverage:

Feb 15 2018

BRIEF-Arrowhead Pharmaceuticals Reports Fiscal 2018 Q1 Results

* ARROWHEAD PHARMACEUTICALS REPORTS FISCAL 2018 FIRST QUARTER RESULTS

Feb 09 2018

BRIEF-Arrowhead Pharmaceuticals Announces Pricing Of Underwritten Public Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PRICING OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

Jan 18 2018

BRIEF-Arrowhead Pharma Announces Proposed Underwritten Offering Of Common Stock

* ARROWHEAD PHARMACEUTICALS ANNOUNCES PROPOSED UNDERWRITTEN OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage:

Jan 17 2018

Earnings vs. Estimates